Amplimexon imexon: Interim Phase I/II data

Interim data from 27 evaluable patients in an open-label, U.S. Phase I/II trial showed that Amplimexon plus dacarbazine (DTIC) treatment led to a partial response in 5 patients and 7 patients had stab...